
|Articles|June 1, 2003
- Psychiatric Times Vol 20 No 6
- Volume 20
- Issue 6
After the Famous Poet
Poetry of the Times
Advertisement
After the Famous Poet
recites a poem
that ends with "a purple stain,"
she recalls how she went to war
with another famous poet
about whether it is proper
to end a poem with a color.
And I envy the famous poet
for living in a world
where battles over colorful words
can feel like life and death.
For years ago I chose a world
where colorful words
like "green meconium stain"
or "peau d'orange"
describe deformity beyond metaphor,
a war where flesh is cut and colored
to let us read the body's text,
our precise choice of words
as brilliant and final
as the last line of any poem.
Articles in this issue
over 23 years ago
Confidentiality Under Fireover 23 years ago
Stigma Continues in Hollywoodover 23 years ago
The Art of the Unconsciousover 23 years ago
Psychiatrists Strive to Assure Patients' Safetyover 23 years ago
Conference Probes Pathology of Self-Awarenessover 23 years ago
Music Therapy With Emotionally Disturbed Childrenover 23 years ago
The Assessment of Danger in Everyday Practiceover 23 years ago
The Other Side of the Storyover 23 years ago
Using Creativity to Explore in PsychotherapyAdvertisement
Related to this article

How VA clinicians treat veterans’ PTSD while managing suicide risk, using shared decisions, safety planning, and phase-based trauma therapies.

RADIANT phase 2 shows once-daily remlifanserin eases Alzheimer’s psychosis symptoms with placebo-like safety, advancing pivotal trials.

Discover how integrated psychotherapy—CBTp, family support, and relapse plans—boosts schizophrenia recovery alongside antipsychotics.

FDA grants Breakthrough Device status to NET Recovery’s tACS wearable, aiming to curb cocaine and meth use and close a major treatment gap.

Learn how IPV shapes mental health from pregnancy to adulthood, and how clinicians assess risk, plan safety, and treat victims and perpetrators.

Early trial shows investigational orexin-2 agonist ALKS 7290 improves adult ADHD symptoms in 14 days, with tolerable safety, paving way for phase 2.

Open-label extension data show fasedienol appears well tolerated and steadily improves social anxiety scores with as-needed intranasal use, as Vistagen plans FDA discussions.

A case report and review of 13 similar cases suggest that late-onset clozapine neutropenia may sometimes reflect neutrophil margination rather than marrow suppression, with corticosteroids, granulocyte colony-stimulating factor, or lithium as possible, carefully monitored paths to continuing treatment.
Advertisement
Advertisement
Trending on Psychiatric Times
1
FDA Grants Breakthrough Device Designation to NET Recovery's Device for Stimulant Use Disorder
2
Using Psychotherapy for the Prevention of Relapse in Schizophrenia
3
Positive Phase 2 Topline Results: Remlifanserin for the Treatment of Alzheimer Disease Psychosis
4
Treating PTSD Among Veterans at Risk for Suicide
5
